Domvanalimab - Arcus Biosciences
Alternative Names: AB 154; GS-0154Latest Information Update: 10 Feb 2025
Price :
$50 *
At a glance
- Originator Abmuno Therapeutics
- Developer Arcus Biosciences; AstraZeneca; Gilead Sciences; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastrointestinal cancer; Non-small cell lung cancer
- Phase II Liver cancer
- Phase I/II Cancer; Pancreatic cancer
- No development reported Glioblastoma
Most Recent Events
- 10 Feb 2025 CTP Push 298814: updated trial completion info in KDM and HE added
- 24 Jan 2025 Hospices Civils de Lyon plans to initiate a phase II (IMMUNORARE5) trial for rare cancers (Combination therapy, late-stage disease) in France (IV) (NCT06790706)
- 23 Jan 2025 Arcus Biosciences completes the phase I trial for Cancer (Monotherapy, Combination therapy, Late-stage disease) in Australia, USA (IV) (NCT03628677)